The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.
